About minerva neurosciences inc - NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
NERV At a Glance
Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, Massachusetts 01803
| Phone | 1-617-600-7373 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -293,423,177.00 | |
| Sector | Health Technology | Employees | 7 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NERV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.098 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 3.917 |
NERV Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -41,917,596.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NERV Liquidity
| Current Ratio | 36.28 |
| Quick Ratio | 36.28 |
| Cash Ratio | 35.976 |
NERV Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -434.339 |
| Return on Equity | N/A |
| Return on Total Capital | 387.173 |
| Return on Invested Capital | N/A |
NERV Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -85.717 |
| Total Debt to Total Assets | 66.309 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -85.717 |